GABA Therapeutics
Newport Beach, US · Founded 2019 · Delaware corporation · 1 known investors
Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
IJ
Ian John MasseyNamed on SEC filing
RG
Richard Gregory FarrellCFO
FB
Florian BrandNamed on SEC filing
ML
Matthias LuzNamed on SEC filing
CF
Christian FibigerNamed on SEC filing
OD
Olivier DasseNamed on SEC filing
DG
David George PutmanNamed on SEC filing
DS
Dr. SaltarelliExecutive (CNS drug development)
RT
Roger TungExecutive
KK
Kathryn KingClinical Development Executive
Investors · 1
Reported raises · per SEC filings
Form D private placements$22M disclosed across 2 rounds · 2019–2023
▶$500KraisedOct 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$500KraisedOct 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ryan BarrettDirector
- H. Christian FibigerDirector
- Srinivas RaoDirector
- Mario SaltarelliExecutive Officer, Director
- Richard FarrellExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$21.5MraisedOct 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$21.5MraisedOct 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian John MasseyExecutive Officer, Director
- Richard Gregory FarrellExecutive Officer, Director
- Florian BrandDirector
- Matthias LuzDirector
- Christian FibigerDirector
- Olivier DasseExecutive Officer
- David George PutmanExecutive Officer
- Amount sold
- $21.5M
- Proceeds to insiders
- $873.8K
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does GABA Therapeutics do?
- Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.
- Who are GABA Therapeutics's investors?
- GABA Therapeutics's investors include Robin Hood Ventures.
- How much funding has GABA Therapeutics raised?
- GABA Therapeutics has disclosed $22M raised across 2 rounds.
- Where is GABA Therapeutics headquartered?
- GABA Therapeutics is headquartered in Newport Beach, US.